Evidence map›Paper›PMID 39442921›Full record

Trial reportBritish journal of haematology2025

Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.

Linmiao Jiang, Martin Dreyling, Olivier Hermine, Ulrich Mansmann, Jan Walewski, Vincent Ribrag, Catherine Thieblemont, Christiane Pott, Emmanuel Bachy, Pierre Feugier and 3 more

Abstract readClinical Trial, Phase IIIRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Linmiao JiangInstitute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-9009-4236
Martin DreylingDepartment of Internal Medicine III, LMU University Hospital Munich, Munich, Germany.
Olivier HermineDepartment Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, Paris, France.
Ulrich MansmannInstitute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Munich, Germany.
Jan WalewskiDepartment of Lymphoid Malignancies, The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Vincent RibragInstitut Gustave Roussy, Villejuif, France.ORCID https://orcid.org/0000-0002-5221-353X
Catherine ThieblemontAssistance Publique-Hôpitaux de Paris, Hemato-Oncologie, Hôpital Saint Louis, University of Paris, Paris, France.
Christiane PottSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
Emmanuel BachyHospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Université Claude Bernard, Pierre Bénite, France.
Pierre FeugierService d'Hematologie, Vandoevre les Nancy, France.
Kai HübelKlinik I für Innere Medizin, Universität zu Köln, Köln, Germany.
Martin SchumacherInstitute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Eva HosterInstitute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-0749-1389

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During a fatal disease, patients often request updated information on their prognosis. After patients have already survived a certain time, conditional survival captures their future survival probability. We investigated conditional overall and failure-free survival in 473 younger mantle cell lymphoma (MCL) patients from a randomized phase III trial comparing immunochemotherapies R-CHOP and alternating R-CHOP/R-DHAP before autologous transplantation. Using conditional Kaplan-Meier method and Cox regression, we estimated subsequent survival of patients who had survived 1-8 years, considering MIPI, Ki-67, and treatment failure status. Starting at a lower level, R-CHOP patients only showed increasing subsequent survival as they survived longer (5-year conditional survival: 72% and 81% after surviving 1 and 7 years), while R-CHOP/R-DHAP patients had stable future survival over time (77% and 78%). The prognostic value of MIPI diminished after 3 years in R-CHOP patients but remained unchanged after R-CHOP/R-DHAP. Patients with treatment failure had markedly inferior survival compared with those in ongoing remission, regardless of the time survived. The longer patients remained in remission, the longer they would stay free of treatment failures. Our results enable personalized counselling for younger MCL patients by offering dynamic prognosis and underscore the importance of highly effective first-line treatment to improve survival.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Mantle-CellAdultCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleHumansMaleMiddle AgedPrednisonePrognosisRituximabSurvival RateVincristineCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineconditional survivalimmunochemotherapymantle cell lymphomaprognosis

Identifiers

PMID39442921
PMCPMC11739754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.